Cancer: New Frontiers in Oncology — What Research Revealed in 2025

 

 

The State of Cancer Treatment in 2025

Cancer research in 2025 has been defined by a convergence of three transformative forces:
the maturation of immunotherapy as a standard-of-care approach across multiple tumour
types; the explosion of antibody-drug conjugates (ADCs) that deliver chemotherapy directly
to cancer cells while sparing healthy tissue; and the deepening of precision medicine —
matching treatments to the specific molecular fingerprint of each patient's tumour.
The result is a treatment landscape that would have been unrecognisable a decade ago —
patients with cancers previously considered untreatable are achieving durable remissions,
and the concept of cancer as an invariably fatal disease is being fundamentally challenged.

 

Immunotherapy: Cementing Its Role Across Cancer Types

Immune checkpoint inhibitors — drugs that release the brakes on the immune system's
ability to recognise and destroy cancer cells — have become foundational in the treatment of
lung, kidney, bladder, head and neck, and melanoma cancers. In 2025, the evidence base
has deepened significantly:
For lung cancer, long-term follow-up data from KEYNOTE and CheckMate trials confirm
durable 5-year survival rates in 15–30% of patients with advanced NSCLC treated with
pembrolizumab — a milestone unimaginable with chemotherapy alone. For previously
untreatable oesophageal and gastric cancers, nivolumab and pembrolizumab combinations
with chemotherapy have become standard of care, reducing mortality risk by 22–38%.
Neoadjuvant immunotherapy — giving immunotherapy before surgery to shrink tumours and
train the immune system — emerged as a major clinical strategy in 2025. The approach has
shown complete pathological responses in 35–60% of patients across multiple solid tumour
types, suggesting that combining surgery with pre-operative immune activation may
dramatically improve long-term outcomes.

 

Antibody-Drug Conjugates (ADCs): Precision Chemotherapy

ADCs represent one of the most significant advances in oncology in a generation. These
engineered molecules consist of a monoclonal antibody that targets a specific protein on
cancer cells, linked to a potent chemotherapy payload. The antibody "delivers" the chemo
directly to cancer cells, dramatically reducing systemic toxicity. In 2025, ADCs expanded
across multiple cancer types:
▸ Trastuzumab deruxtecan (T-DXd / Enhertu) for HER2-positive breast, gastric, and lung
cancers demonstrated survival benefits across all three tumour types, making it one of the
most impactful oncology drugs of the decade
▸ Sacituzumab govitecan (Trodelvy) for triple-negative breast cancer (TNBC) combined
with pembrolizumab showed a 35% reduction in progression or death versus chemotherapy
plus pembrolizumab in the ASCENT-04 trial
▸ Datopotamab deruxtecan became the first ADC to demonstrate overall survival benefit in
first-line metastatic TNBC, marking a major milestone at ESMO 2025

 

 

Liquid Biopsies: Cancer Detection Revolutionised

Circulating tumour DNA (ctDNA) — fragments of DNA shed by cancer cells into the
bloodstream — is transforming oncology from diagnosis through treatment monitoring. In
2025, major cancer conferences unveiled ctDNA-guided treatment as a real-time precision
medicine tool: liquid biopsies are now enabling detection of treatment resistance weeks

before radiological progression, allowing oncologists to switch therapies before clinical

deterioration.
A January 2026 study showed that risk-stratified breast cancer screening — based on
genetics, health history, and lifestyle factors rather than age-based mammography —
reduced advanced-stage cancer diagnoses, pointing toward a personalised screening future.

 

 

CAR-T Cell Therapy: From Blood Cancers to Solid Tumours

Chimeric antigen receptor T-cell (CAR-T) therapies have been transformative in
haematological malignancies (leukaemia, lymphoma, myeloma), achieving complete
remissions in patients who had exhausted all other options. The frontier in 2025 is solid
tumours — notoriously difficult for CAR-T due to their immunosuppressive
microenvironment. Early clinical data from trials targeting mesothelin, GD2, HER2, and
PSMA in solid tumours is encouraging, with several phase 2 trials delivering early evidence
of activity in lung, ovarian, and brain cancers.

 

 

PARP Inhibitors: Targeted Therapy Expands

PARP inhibitors — drugs that exploit the inability of BRCA-mutated cancer cells to repair
DNA damage — have moved from ovarian and breast cancer into prostate and pancreatic
cancers. Olaparib combined with abiraterone reduced risk of progression or death by 76%
versus abiraterone alone in BRCA-mutated metastatic castration-resistant prostate cancer.
In 2025, expanded genetic testing is identifying more patients eligible for this class of drugs
across multiple cancer types.

 

 

What Patients Can Do: Evidence-Based Cancer Prevention

While treatments advance, prevention remains the most powerful tool. The evidence for
lifestyle-based risk reduction is unambiguous:
▸ Not smoking remains the single most impactful cancer prevention act — responsible for
85% of lung cancers and strongly linked to 15 other cancer types
▸ Maintaining healthy body weight: obesity is now recognised as a cause of 13 cancer
types, including breast, colon, oesophageal, kidney, and pancreatic
▸ Physical activity: 30+ minutes daily of moderate exercise reduces risk of colon, breast,
and endometrial cancers by 20–30%
▸ Limiting alcohol: alcohol is a Group 1 carcinogen linked to 7 cancer types — any
consumption increases risk
▸ Screening: regular mammography, colonoscopy, cervical smears, and PSA testing
dramatically reduce cancer mortality through early detection
▸ HPV and Hepatitis B vaccination: preventing the viral infections that cause cervical and
liver cancer respectively

 

 

References

[1] Cortés J et al. Pembrolizumab plus Chemotherapy in Triple-Negative Breast Cancer. NEJM.
2022;387:217-226. doi:10.1056/NEJMoa2202809
[2] Modi S et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. NEJM.
2022;386:610-621. doi:10.1056/NEJMoa2114035
[3] Schmid P et al. ASCENT-04: Sacituzumab govitecan plus pembrolizumab in advanced TNBC. ASCO
2025.
[4] Breast Cancer Research Foundation. 5 Breast Cancer Breakthroughs from 2025. bcrf.org, January
2026.
[5] Wild CP, Weiderpass E, Stewart BW (eds). World Cancer Report: Cancer Research for Cancer
Prevention. IARC Press, 2020. ISBN 9789283204299.
[6] Baptist Health. Breast Cancer Research Updates for 2025. physicianresources.baptisthealth.net,
October 2025.